The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
Two months later, the agency leaned on the report to sue Caremark, Express Scripts and Optum Rx, which jointly account for 80% of U.S. prescriptions, and alleged they artificially inflated the cost of ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...
Specifically, the FTC’s first report found Caremark, Express Scripts and Optum Rx were prioritizing access to high-cost drugs in return for larger discounts from drugmakers and giving their own ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.
FTC’s report focused on three largest PBMs: CVS Health Corporation’s CVS Caremark, The Cigna Group’s CI Express Scripts, and UnitedHealth Group Incorporated’s UNH Optum Rx. This report ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback